Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A One-year Partial Double-blinded, Randomized, Multi-center, Multi-national Study to Assess the Effects of Combination Therapy of Annual Zoledronic Acid (5 mg) and Daily Subcutaneous Teriparatide (2mcrg) on Postmenopausal Women With Severe Osteoporosis

NCT00439244 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00439244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00439244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A One-year Partial Double-blinded, Randomized, Multi-center, Multi-national Study to Assess the Effects of Combination Therapy of Annual Zoledronic Acid (5 mg) and Daily Subcutaneous Teriparatide (2mcrg) on Postmenopausal Women With Severe Osteoporosis
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2006
Completion date
February 28, 2009
Enrollment
412 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis